Lidoflazine

In today's article we are going to talk about Lidoflazine, a topic that has been the subject of debate and study for many years. Since its appearance, Lidoflazine has generated interest in various communities and has been the subject of discussion in different areas. In this article we will analyze the most relevant aspects of Lidoflazine, exploring its origins, its implications and its impact on current society. Additionally, we will address the different perspectives that exist around Lidoflazine, as well as possible solutions or approaches to address the challenges it poses. We hope that this article will be of interest to those seeking to better understand Lidoflazine, and that it can serve as a starting point for future reflections and discussions on this topic.

Lidoflazine
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 2-piperazin-1-yl]-N-(2,6-dimethylphenyl)acetamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.020.285 Edit this at Wikidata
Chemical and physical data
FormulaC30H35F2N3O
Molar mass491.627 g·mol−1
3D model (JSmol)
Melting point159 to 161 °C (318 to 322 °F)
Solubility in waterAlmost insoluble in water(<0.01%); Very soluble in chloroform(>50%); mg/mL (20 °C)
  • CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
  • InChI=1S/C30H35F2N3O/c1-22-5-3-6-23(2)30(22)33-29(36)21-35-19-17-34(18-20-35)16-4-7-28(24-8-12-26(31)13-9-24)25-10-14-27(32)15-11-25/h3,5-6,8-15,28H,4,7,16-21H2,1-2H3,(H,33,36) ☒N
  • Key:ZBIAKUMOEKILTF-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Lidoflazine is a piperazine calcium channel blocker. It is a coronary vasodilator with some antiarrhythmic action.[1] Lidoflazine was discovered at Janssen Pharmaceutica in 1964.

Physical properties

Solubility at room temperature

Extracted from[1]

Solvent 0.01

N

0.1

N

% pH % pH
Hydrochloric Acid 0.4 3.0 0.7 1.9
Tartaric Acid 0.3 3.1 1.0 2.5
Citric Acid 0.3 3.1 0.5 2.5
Lactic Acid 0.2 3.4 0.7 2.9
Acetic Acid 0.1 3.5 0.4 3.8

References

  1. ^ a b Schaper WK, Xhoneux R, Jageneau AH, Janssen PA (May 1966). "The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator". The Journal of Pharmacology and Experimental Therapeutics. 152 (2): 265–274. PMID 5944369.

Further reading

  • Schaper WK, Xhonneux R, Jageneau AH (November 1965). "Stimulation of the coronary collateral circulation by lidoflazine (R 7904)". Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie. 252 (1): 1–8. doi:10.1007/bf00246424. PMID 4222721. S2CID 31959581.

[1]


Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

  1. ^ Zhou PZ, Babcock J, Liu LQ, Li M, Gao ZB (June 2011). "Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules". Acta Pharmacologica Sinica. 32 (6): 781–788. doi:10.1038/aps.2011.70. PMC 4085723. PMID 21623390.